```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1600dxk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08   "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09   BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09   ZDB will be removed from STN
 NEWS  5  Apr 19   US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS  6  Apr 22   Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS  7  Apr 22   BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22   Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03   New e-mail delivery for search results now available
 NEWS 10  Jun 10   MEDLINE Reload
 NEWS 11  Jun 10   PCTFULL has been reloaded
 NEWS 12  Jul 02   FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22   USAN to be reloaded July 28, 2002;
                   saved answer sets no longer valid
 NEWS 14  Jul 29   Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30   NETFIRST to be removed from STN
 NEWS 16  Aug 08   CANCERLIT reload
 NEWS 17  Aug 08   PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08   NTIS has been reloaded and enhanced
 NEWS 19  Aug 19   Aquatic Toxicity Information Retrieval (AQUIRE)
                   now available on STN
 NEWS 20  Aug 19   IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19   The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26   Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03   JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16   Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16   CA Section Thesaurus available in CAPLUS and CA
 NEWS 26  Oct 01   CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 27  Oct 21   EVENTLINE has been reloaded
 NEWS 28  Oct 24   BEILSTEIN adds new search fields
 NEWS 29  Oct 24   Nutraceuticals International (NUTRACEUT) now available on
STN
 NEWS 30  Oct 25   MEDLINE SDI run of October 8, 2002
 NEWS 31  Nov 18   DKILIT has been renamed APOLLIT
 NEWS 32  Nov 25   More calculated properties added to REGISTRY
 NEWS 33  Dec 02   TIBKAT will be removed from STN
 NEWS 34  Dec 04   CSA files on STN
 NEWS 35  Dec 17   PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 36  Dec 17   TOXCENTER enhanced with additional content
 NEWS 37  Dec 17   Adis Clinical Trials Insight now available on STN
 NEWS 38  Dec 30   ISMEC no longer available
 NEWS 39  Jan 13   Indexing added to some pre-1967 records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
```

```
                AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS      STN Operating Hours Plus Help Desk Availability
NEWS INTER      General Internet Information
NEWS LOGIN      Welcome Banner and News Items
NEWS PHONE      Direct Dial and Telecommunication Network Access to STN
NEWS WWW        CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 12:17:12 ON 20 JAN 2003

=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:17:19 ON 20 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 JAN 2003  HIGHEST RN 479481-27-1
DICTIONARY FILE UPDATES:  19 JAN 2003  HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e paclitaxel/cn
E1            1      PACKY N 50/CN
E2            1      PACKZOL/CN
E3            1 --> PACLITAXEL/CN
E4            1      PACLITAXEL 2'-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E5            1      PACLITAXEL 6.ALPHA.-HYDROXYLASE/CN
E6            1      PACLITAXEL 6.ALPHA.-MONOOXYGENASE/CN
E7            1      PACLITAXEL 7-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E8            1      PACLITAXEL C/CN
```

```
E9              1     PACLITAXEL DIHYDRATE/CN
E10             1     PACLITAXEL SUCCINATE/CN
E11             1     PACLITAXEL-2'-ACETATE/CN
E12             1     PACLITAXEL-3'-14C/CN

=> s e3
L1              1 PACLITAXEL/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   33069-62-4  REGISTRY
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester, (.alpha.R,.beta.S)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
     deriv.
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
     6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
     dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.
     ,12.alpha.,12a.alpha.,12b.alpha.]]-
CN   Tax-11-en-9-one,
5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-
     hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with
(2R,3S)-N-benzoyl-3-
     phenylisoserine (8CI)
OTHER NAMES:
CN   ABI 007
CN   BMS 181339-01
CN   NSC 125973
CN   Paclitaxel
CN   Plaxicel
CN   Taxol
CN   Taxol A
CN   Yewtaxan
FS   STEREOSEARCH
MF   C47 H51 N O14
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
       CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*,
       DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB,
       IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PHARMASEARCH,
       PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL,
VETU
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (-).
```



6727 REFERENCES IN FILE CA (1962 TO DATE)
365 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6752 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d rn cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 33069-62-4 REGISTRY
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
CN Tax-11-en-9-one,
5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI)

OTHER NAMES:
CN ABI 007
CN BMS-181339-01
CN NSC 125973
CN **Paclitaxel**
CN Plaxicel
CN Taxol
CN Taxol A
CN Yewtaxan

=> e docetaxel/cn
E1 1 DOCENTAL/CN
E2 1 DOCETAXAL/CN

```
E3            1 --> DOCETAXEL/CN
E4            1     DOCETAXEL HEMIHYDRATE/CN
E5            1     DOCETAXEL TRIHYDRATE/CN
E6            1     DOCEVITA/CN
E7            1     DOCEYLPENTADECYL ACRYLATE-METHYL ACRYLATE-1-OCTADECENE
POLYM
                    ER/CN
E8            1     DOCHC/CN
E9            1     DOCHLOXYTHEPIN/CN
E10           1     DOCI/CN
E11           1     DOCIBIN/CN
E12           1     DOCIGRAM/CN

=> s e3
L2            1 DOCETAXEL/CN

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   114977-28-5  REGISTRY
CN   Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-
     .alpha.-hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
     (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-
     trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
     deriv.
CN   Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-
     .alpha.-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-

2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester,
[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S
     *),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
OTHER NAMES:
CN   Docetaxel
CN   RP 56976
CN   Taxotere
FS   STEREOSEARCH
DR   216252-50-5
MF   C43 H53 N O14
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
       CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL,
       DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*,
       MSDS-OHS, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE,
TOXCENTER,
       USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```



1367 REFERENCES IN FILE CA (1962 TO DATE)
63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1377 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.48	15.69

STN INTERNATIONAL LOGOFF AT 12:20:36 ON 20 JAN 2003

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1600dxk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 26  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 27  Oct 21  EVENTLINE has been reloaded
 NEWS 28  Oct 24  BEILSTEIN adds new search fields
 NEWS 29  Oct 24  Nutraceuticals International (NUTRACEUT) now available on
STN
 NEWS 30  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 31  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 32  Nov 25  More calculated properties added to REGISTRY
 NEWS 33  Dec 02  TIBKAT will be removed from STN
 NEWS 34  Dec 04  CSA files on STN
 NEWS 35  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 36  Dec 17  TOXCENTER enhanced with additional content
 NEWS 37  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 38  Dec 30  ISMEC no longer available
 NEWS 39  Jan 13  Indexing added to some pre-1967 records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
```

```
NEWS HOURS     STN Operating Hours Plus Help Desk Availability
NEWS INTER     General Internet Information
NEWS LOGIN     Welcome Banner and News Items
NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 12:05:32 ON 20 JAN 2003

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 20 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 JAN 2003  HIGHEST RN 479481-27-1
DICTIONARY FILE UPDATES:  19 JAN 2003  HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e 4-desacetyl-4-methylcarbonate taxol/cn
E1            1     4-DEOXYWILFORINE/CN
E2            1     4-DESACETOXYVINDOLINE/CN
E3            0 --> 4-DESACETYL-4-METHYLCARBONATE TAXOL/CN
E4            1     4-DESACETYLNEOSOLANIOL/CN
E5            1     4-DESACETYLPACLITAXEL 4-METHYL CARBONATE/CN
E6            1     4-DESACETYLVINBLASTINE/CN
E7            1     4-DESACETYLVINBLASTINE 3-CARBOHYDRAZIDE/CN
E8            1     4-DESACETYLVINBLASTINE 3-CARBOXYHYDRAZIDE/CN
E9            1     4-DESACETYLVINBLASTINE N-OXIDE/CN
E10           1     4-DESACETYLVINCALEUKOBLASTINE/CN
```

```
E11          1     4-DESACETYLVINCALEUKOBLASTINE
3-(2-CHLOROETHYL)CARBOXAMIDE/C
                   N
E12          1     4-DESACETYLVINCALEUKOBLASTINE 3-(2-CHLOROETHYL)CARBOXAMIDE
S
                   ULFATE/CN

=> s e5
L1           1 "4-DESACETYLPACLITAXEL 4-METHYL CARBONATE"/CN

=> d rn cn

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   172481-83-3  REGISTRY
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
     [(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
     4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
     7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.a
     lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
OTHER NAMES:
CN   4-Desacetylpaclitaxel 4-methyl carbonate


=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   172481-83-3  REGISTRY
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
     [(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
     4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
     7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.a
     lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
OTHER NAMES:
CN   4-Desacetylpaclitaxel 4-methyl carbonate
FS   STEREOSEARCH
MF   C47 H51 N O15
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, SYNTHLINE, TOXCENTER, USPAT2,
USPATFULL

Absolute stereochemistry.
```



9 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> fil .carb
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        10.78      10.99

FILE 'MEDLINE' ENTERED AT 12:10:29 ON 20 JAN 2003

FILE 'BIOSIS' ENTERED AT 12:10:29 ON 20 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHDS' ENTERED AT 12:10:29 ON 20 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CAPLUS' ENTERED AT 12:10:29 ON 20 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
L2            9 L1

=> d l9 abs ibib 1-9
L9 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l2 abs ibib 1-9

L2   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2003 ACS
GI
```



I



II

AB The present invention provides a synergistic method for the treatment of cancer which comprises administering a synergistically, therapeutically effective amt. of: (i) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (ii) a compd. of formula [I; R1 = Cl, Br, CN, substituted Ph, substituted pyridyl; R2 = alkyl, aralkyl; R3,R5 = substituted alkyl, aryl, heterocycle; R4 = H, alkyl; Z1 =
CO, SO2, CO2, SO2N(R5); n = 1,2] or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical compn. for the synergistic treatment of cancer which comprises at least one agent
selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compd. of formula I, and a pharmaceutically acceptable carrier. Synergism was obsd. when non-proliferating tumor cells were treated with diazepine II.cntdot.HCl and paclitaxel (III) simultaneously or when III preceded II.cntdot.HCl.

ACCESSION NUMBER: 2001:730715 CAPLUS
DOCUMENT NUMBER: 135:288636
TITLE: Synergistic methods and compositions for treating cancer using two or more anticancer agents
INVENTOR(S): Lee, Francis Y.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072721	A2	20011004	WO 2001-US9193	20010322
WO 2001072721	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1272193	A2	20030108	EP 2001-920653	20010322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

US 2002002162 A1 20020103 US 2001-817456 20010326
PRIORITY APPLN. INFO.: US 2000-192278P P 20000327
WO 2001-US9193 W 20010322
OTHER SOURCE(S): MARPAT 135:288636

L2 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A method for inhibiting hair loss and/or promoting hair growth in chemotherapy and/or radiation therapy patients wherein the (R)-enantiomer of 4-[[(cyanoimino)-[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitril e is administered prior to, simultaneous with and/or after chemotherapy and/or radiation treatment. There was a remarkable difference between the 1-(R)-enantiomer and the 2-(S)enantiomer in their effect on hair follicle stimulation; in particular the (R)-enantiomer had a faster onset of action compared to the corresponding (S)-enantiomer. While the IC50 for vasorelaxant potency of the (R)-enantiomer is 47.+-.17 nM vs. 157.+-.35 nM for the (S)-enantiomer, the hair growth promoting ability of the (R)-enantiomer for producing hair growth within 11 days of treatment is 8 times greater than the corresponding (S)-enantiomer.
ACCESSION NUMBER: 2001:658077 CAPLUS
DOCUMENT NUMBER: 135:205580
TITLE: Method for inhibiting or treating chemotherapy-induced hair loss
INVENTOR(S): Atwal, Karnail S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 447,002.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001020038	A1	20010906	US 2001-805347	20010313
US 6458835	B2	20021001		
US 6013668	A	20000111	US 1998-119884	19980721
ZA 9807220	A	20000214	ZA 1998-7220	19980812
US 6472427	B1	20021029	US 1999-447002	19991122
US 6262122	B1	20010717	US 2000-615345	20000712

PRIORITY APPLN. INFO.: US 1997-55568P P 19970813
US 1998-71364P P 19980115
US 1998-119884 A1 19980721
US 1999-447002 A2 19991122

L2 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A process for the synthesis of C-4 Me carbonate paclitaxel analog from 10-deacetylbaccatin III is described by the selective redn. of the acetate at the C-4 position of 10-deacetylbaccatin III using Red-Al.
ACCESSION NUMBER: 2001:115139 CAPLUS
DOCUMENT NUMBER: 134:163187
TITLE: Process for the preparation of a paclitaxel C-4 methyl carbonate analog
INVENTOR(S): Kant, Joydeep

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010856	A1	20010215	WO 2000-US21260	20000803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1206461	A1	20020522	EP 2000-952478	20000803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6248908	B1	20010619	US 2000-635553	20000810
US 2001044549	A1	20011122	US 2001-813085	20010320
US 6353120	B2	20020305		

PRIORITY APPLN. INFO.: US 1999-148392P P 19990811
WO 2000-US21260 W 20000803
US 2000-635553 A3 20000810

OTHER SOURCE(S): CASREACT 134:163187
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Novel reaction conditions for the cleavage of silyl ethers from silyl protected taxane precursors I {R1 = Me, Ph, 4-Me-, 4-NO2-C6H4, cyclohexyl; R2 = Me, Et, n-Pr, CMe3, Bu, pentyl, Ph, 4-NO2-C6H4, cyclopropyl, cyclobutyl,OMe; R3 = Si[(CHMe2)2]2OMe, SiEt3, SiMe3, SiMe2CMe3; R4 = H, Me, Ph, acetyl, benzoyl, pentanoyl; R5 = (4S,5R)-4,5-dihydro-2,4-diphenyl-5-oxazolecarbonyl, (2R,3S)-R7CH(NHCOR8)CHR6CO-; R6 = H, F, OH, OMe, OSiEt3, OSiMe2CMe3, OCMe2OMe; R7 - Ph, CMe3, CHMe2; R8 = Ph, CMe3, OCMe3, CH3CM3; cyclobutyl, cyclohexyloxy, 2-furyl} to afford the anti-cancer agents paclitaxel and paclitaxel analogs in high yield and quality was described. Paclitaxel was prepd. from a taxane precursor by treating the taxane precursor with a strong acid, such as trifluoroacetic acid, in a solvent such as aq. acetic acid, such that the amt. and no. of side reactions and taxane impurities are significantly minimized. Also described were the crystn. methods for the isolation of paclitaxel in either of the two crystal forms A or B. Thus, taxane silyl ether II was reacted with trifluoroacetic acid and glacial acetic acid in water for 5-7 h., followed by treatment of the unisolated intermediate with sulfuric acid in water to give paclitaxel in 86.9% yield.

ACCESSION NUMBER: 2000:824239 CAPLUS
DOCUMENT NUMBER: 133:362862
TITLE: Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (Taxol) and paclitaxel analogues
INVENTOR(S): Singh, Ambarish; Weaver, Raymond E., Jr.; Powers, Gerald L.; Rosso, Victor W.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069840	A1	20001123	WO 2000-US12469	20000508
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1178979	A1	20020213	EP 2000-932151	20000508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002544269	T2	20021224	JP 2000-618257	20000508
US 6184395	B1	20010206	US 2000-571234	20000516

PRIORITY APPLN. INFO.: US 1999-134469P P 19990517
WO 2000-US12469 W 20000508

OTHER SOURCE(S): CASREACT 133:362862; MARPAT 133:362862
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L2 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A series of 98 paclitaxel analogs were investigated using the comparative mol. field anal. (CoMFA) and a high predictive 3D-QSAR model with a significant cross-validated .gamma.cv2, conventional .gamma.2, and predictive .gamma.pred.2 equaling to 0.714, 0.901, 0.812, resp., was obtained. It revealed that the changes of the C-13 side chain groups, esp. 2'-OH, affected the activity significantly and others did less relatively. It also showed that the model was significant for the research and development of novel paclitaxel analogs to reduce the blind flight during drug designing.

ACCESSION NUMBER: 2000:218668 CAPLUS
DOCUMENT NUMBER: 133:255
TITLE: Studies on the quantitative structure-activity relationships of paclitaxel analogs
AUTHOR(S): Shi, Bing-Xing; Liang, Shi-Le; Yuan, Ying-Jin; Sun, Ming; Miao, Fang-Ming
CORPORATE SOURCE: Department of Biochemical Engineering, Tianjin University, Tianjin, 300072, Peop. Rep. China
SOURCE: Gaodeng Xuexiao Huaxue Xuebao (2000), 21(3), 401-406
CODEN: KTHPDM; ISSN: 0251-0790
PUBLISHER: Gaodeng Jiaoyu Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L2 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB The semisynthesis and biol. activity of paclitaxel (Taxol) analogs in which the oxygen atom in ring D is substituted by a sulfur or a selenium atom is presented. These derivs. were synthesized and tested in order to make more transparent the role of the oxetane ring in the biol. activity of paclitaxel. The sulfur derivs. were found to be less active than paclitaxel in biol. assays, while the selenium deriv. could not be converted to its 4-acyl analog. The results with the sulfur analogs suggest that the oxygen atom in the oxetane ring plays an important role in the mechanism by which paclitaxel exhibits its anticancer activity.

ACCESSION NUMBER: 1999:202337 CAPLUS
DOCUMENT NUMBER: 131:5390
TITLE: Synthesis and Biological Evaluation of Novel

Paclitaxel (Taxol) D-Ring Modified Analogs
AUTHOR(S): Gunatilaka, A. A. Leslie; Ramdayal, Frank D.; Sarragiotto, Maria H.; Kingston, David G. I.; Sackett, Dan L.; Hamel, Ernest
CORPORATE SOURCE: Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061-0212, USA
SOURCE: Journal of Organic Chemistry (1999), 64(8), 2694-2703
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A series of 94 paclitaxel analogs exhibiting antitumor activity by promoting the assembly of microtubules and inhibiting the disassembly process of microtubules to tubulin were investigated using the comparative mol. field anal. (CoMFA) method. These compds. belonging to 10 structural classes were randomly divided into a training set of 80 compds. and a test set of 14 compds. Since the 3-dimensional structure of ligand-receptor complex is unknown, from x-ray and NMR data, the authors rationally selected the 3-dimensional structure of paclitaxel in a polar soln. as the active conformation and starting structure for mol. modeling, the other mols. were aligned using this mol. model as the template. The most optimal CoMFA yielded a 2-component model, with significant cross-validation r2cv of 0.640 and conventional r2 of 0.868. The predictive ability of training set model was tested on the test set of 14 compds. The tests not only revealed the robustness of the CoMFA model but demonstrated that for this model r2pred based on the mean activity of test set compds. can accurately est. external predictivity but r2pred based on the mean activity of training set compds. overestimated the model. The CoMFA model explained why the activity of taxoid is sensitive to the stereochem. of the atoms at C-2' and C-3' positions and the presence of hydroxyl group at C-2' position. The other factors affecting activity were also elucidated according to std. coeff. contour maps of steric and electrostatic fields derived from the CoMFA model.
ACCESSION NUMBER: 1998:31653 CAPLUS
DOCUMENT NUMBER: 128:30043
TITLE: Comparative Molecular Field Analysis of A Series of Paclitaxel Analogs
AUTHOR(S): Zhu, Qiqing; Guo, Zongru; Huang, Niu; Wang, Minmin; Chu, Fengming
CORPORATE SOURCE: Department of Synthetic Medicinal Chemistry Institute of Materia Medica Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100050, Peop. Rep. China
SOURCE: Journal of Medicinal Chemistry (1997), 40(26), 4319-4328
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

L2 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB Several C-13 amidopaclitaxel analogs have been synthesized during the course of our structure-activity relationship study at the C-13 position. These include 4-deacetyl-13-amidopaclitaxel (I; R = H, R' = Bz, R" = Ph), 13-amidopaclitaxel 4-(Me carbonate) derivs. (I; R = CO2Me, R' = Bz, R" = Ph, 2-furyl), and 13-amidopaclitaxel (I; R = Ac, R' = Bz, R" = Ph). None of these novel C-13 amidopaclitaxel analogs retain any activity in the tubulin polymn. assay or the in vitro cytotoxicity assay.

ACCESSION NUMBER: 1996:136175 CAPLUS
DOCUMENT NUMBER: 124:289921
TITLE: Synthesis and Biological Evaluation of C-13 Amide-Linked Paclitaxel (Taxol) Analogs
AUTHOR(S): Chen, Shu-Hui; Farina, Vittorio; Vyas, Dolatrai M.; Doyle, Terrence W.; Long, Byron H.; Fairchild, Craig
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, CONNECTICUT, USA
SOURCE: Journal of Organic Chemistry (1996), 61(6), 2065-70
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:289921

L2 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A large no. of C-4 paclitaxel analogs have been prepd. in the course of our systematic C-4 modification. These include C-4 esters, carbonates, carbamates as well as a C-4 deacetyl derivs. All of these analogs were evaluated in a tubulin polymn. assay as well as in a cytotoxicity assay against a human colon cancer cell line. The potent analogs emerging from these in vitro assays were further evaluated in vivo. With the exception of paclitaxel side chain bearing C-4 carbamates and C-4 arom. esters, most of the C-4 aliph. esters and carbonates were found to possess comparable or superior activity to paclitaxel in vitro. Several C-4 aliph. esters and carbonates also exhibited in vivo activities against i.p. implanted murine M-109 lung carcinoma.

ACCESSION NUMBER: 1995:959365 CAPLUS
DOCUMENT NUMBER: 124:176562
TITLE: Novel C-4 paclitaxel (Taxol) analogs: potent antitumor agents
AUTHOR(S): Chen, Shu-Hui; Wei, Jian-Mei; Long, Byron H.;

Fairchild, Craig A.; Carboni, Joan; Mamber, Steven W.;
Rose, William C.; Johnston, Kathy; Casazza, Anna M.; et al.
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Res. Inst., Wallingford, CT, 06492-7660, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(22), 2741-6
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

=> s 4-desacetyl-4-methylcarbonate(w)taxol?
L3 1 4-DESACETYL-4-METHYLCARBONATE(W) TAXOL?

=> d l3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2002:240547 CAPLUS
DN 136:257231
TI Method for reducing toxicity of combined chemotherapies
IN Minotti, Giorgio; Gianni, Luca
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024179	A2	20020328	WO 2001-US27620	20010906
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001088805	A5	20020402	AU 2001-88805	20010906
	US 2002049170	A1	20020425	US 2001-954953	20010918
PRAI	US 2000-234496P	P	20000922		
	WO 2001-US27620	W	20010906		

=> d l3 abs ibib

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AB Compns. and methods are provided for use in the treatment of cancer. A method for the treatment of cancer is provided comprising administration of **4-desacetyl-4-methylcarbonate taxol** and doxorubicin to a patient in need thereof. Surprisingly, it has been found that 4-desacetyl 4-Me carbonate taxol does not stimulate formation of cardiotoxic metabolic doxorubicin byproducts. Also provided with the present invention is a chemotherapeutic compn. comprising a chemotherapeutically effective amt. of 4-desacetyl 4-Me carbonate taxol and doxorubicin. In a further embodiment of the invention, the

chemotherapeutic compn. is disposed within a pharmaceutically acceptable carrier. Alternatively, each agent, 4-desacetyl 4-Me carbonate taxol and doxorubicin may be formulated sep. to facilitate sequential administration of the compns.

ACCESSION NUMBER: 2002:240547 CAPLUS
DOCUMENT NUMBER: 136:257231
TITLE: Method for reducing toxicity of combined chemotherapies
INVENTOR(S): Minotti, Giorgio; Gianni, Luca
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024179	A2	20020328	WO 2001-US27620	20010906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088805	A5	20020402	AU 2001-88805	20010906
US 2002049170	A1	20020425	US 2001-954953	20010918

PRIORITY APPLN. INFO.: US 2000-234496P P 20000922
WO 2001-US27620 W 20010906

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.95	51.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.51	-6.51

STN INTERNATIONAL LOGOFF AT 12:16:30 ON 20 JAN 2003